FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,664,303 | -44.3% | 2,947,809 | 0.0% | 2.68% | -25.6% |
| Q2 2023 | $13,766,268 | +23.9% | 2,947,809 | 0.0% | 3.60% | +3.8% |
| Q1 2023 | $11,113,240 | +19.7% | 2,947,809 | 0.0% | 3.47% | +11.9% |
| Q4 2022 | $9,285,598 | +4.7% | 2,947,809 | 0.0% | 3.10% | +27.4% |
| Q3 2022 | $8,873,000 | +20.9% | 2,947,809 | 0.0% | 2.43% | +27.2% |
| Q2 2022 | $7,340,000 | -68.0% | 2,947,809 | 0.0% | 1.91% | -54.9% |
| Q1 2022 | $22,905,000 | +86.3% | 2,947,809 | 0.0% | 4.24% | +125.9% |
| Q4 2021 | $12,292,000 | -47.4% | 2,947,809 | 0.0% | 1.88% | -37.4% |
| Q3 2021 | $23,347,000 | -2.8% | 2,947,809 | -0.9% | 3.00% | -40.0% |
| Q2 2021 | $24,028,000 | -25.0% | 2,973,744 | -0.5% | 4.99% | -2.8% |
| Q1 2021 | $32,049,000 | -21.9% | 2,989,644 | -14.4% | 5.14% | -39.8% |
| Q4 2020 | $41,040,000 | +2.6% | 3,492,749 | -0.3% | 8.53% | -19.0% |
| Q3 2020 | $39,994,000 | -27.4% | 3,502,425 | 0.0% | 10.54% | -7.4% |
| Q2 2020 | $55,069,000 | – | 3,502,425 | – | 11.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,543,342 | 3.52% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,664,303 | 2.68% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $4,058,553 | 1.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,354,258 | $3,521,071 | 0.64% |
| Avidity Partners Management LP | 5,781,850 | $15,032,810 | 0.60% |
| Eagle Health Investments LP | 579,769 | $1,507,399 | 0.33% |
| Perceptive Advisors | 2,751,395 | $7,153,627 | 0.24% |
| Ghost Tree Capital, LLC | 243,287 | $632,546 | 0.21% |
| Sio Capital Management, LLC | 246,036 | $639,694 | 0.20% |
| Artal Group S.A. | 1,725,000 | $4,485 | 0.19% |